BiotechTube

mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)] + Durvalumab + Tremelimumab

Phase 1Recruiting
0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Biliary Tract Cancers

Conditions

Biliary Tract Cancers

Trial Timeline

May 27, 2025 → May 1, 2029

NCT ID
NCT06564623

About mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)] + Durvalumab + Tremelimumab

mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)] + Durvalumab + Tremelimumab is a phase 1 stage product being developed by AstraZeneca for Biliary Tract Cancers. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06564623. Target conditions include Biliary Tract Cancers.

What happened to similar drugs?

2 of 20 similar drugs in Biliary Tract Cancers were approved

Approved (2) Terminated (0) Active (18)
✅Tranexamic acid + Standard of CarePfizerApproved
✅abataceptBristol Myers SquibbApproved
🔄Rilvegostomig + Durvalumab + Gemcitabine/CisplatinAstraZenecaPhase 3
🔄durvalumabAstraZenecaPhase 3
🔄Rilvegostomig + Placebo + Capecitabine + Gemcitabine/Cisplatin + S-1 [Tegafur/Oteracil/gimeracil]AstraZenecaPhase 3
🔄Gemcitabine + Cisplatin + Durvalumab + Trastuzumab deruxtecan + RilvegostomigAstraZenecaPhase 3
🔄Durvalumab + Gemcitabine monotherapy + Gemcitabine + cisplatin + Gemcitabine + oxaliplatin + Gemcitabine + carboplatin + Gemcitabine + cisplatin + S-1 + Gemcitabine + S-1 + Gemcitabine + cisplatin + albumin-bound paclitaxelAstraZenecaPhase 3

Hype Score Breakdown

Clinical
6
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06564623Phase 1Recruiting

Competing Products

20 competing products in Biliary Tract Cancers

See all competitors
ProductCompanyStageHype Score
mFOLFOX regimen + MitazalimabAlligator Bioscience ABPhase 2/3
35
Trastuzumab deruxtecanDaiichi SankyoPhase 2
39
Trastuzumab deruxtecanDaiichi SankyoPhase 2
42
Camrelizumab and Apatinib Plus GPSun PharmaceuticalPhase 1/2
28
Recaticimab and Adebrelimab + GP chemotherapySun PharmaceuticalPhase 2
42
Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle)ShionogiPhase 2
35
E6011 + PlaceboEisaiPhase 2
27
LenvatinibEisaiPhase 2
35
gemcitabine + cisplatinEli LillyPhase 2
35
gemcitabine + cisplatinEli LillyPhase 2
35
Ramucirumab + Merestinib + Cisplatin + Gemcitabine + Placebo Oral + Placebo IVEli LillyPhase 2
39
Baricitinib + PlaceboEli LillyPhase 2
27
AbemaciclibEli LillyPhase 2
27
SHR-A1811Jiangsu Hengrui MedicinePhase 2
42
SHR1258Jiangsu Hengrui MedicinePhase 2
27
ApatinibJiangsu Hengrui MedicinePhase 2
31
SHR-1210+GEMOXJiangsu Hengrui MedicinePhase 2
35
Rilvegostomig + Durvalumab + Gemcitabine/CisplatinAstraZenecaPhase 3
47
Durvalumab + Gemcitabine + CisplatinAstraZenecaPre-clinical
33
durvalumabAstraZenecaPhase 3
40